# Xencor, Inc. clinical trials: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Xencor, Inc. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Xencor, Inc.: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/xencor-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07713485 | Study of XmAb412 in Healthy Participants | Xencor, Inc. | Phase 1 | Recruiting | Not Applicable - Healthy Adult Participants | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713485) |
| May 18, 2026 | NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Recruiting | Ovarian Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593092) |
| December 16, 2025 | NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases | Xencor, Inc. | Phase 1 | Recruiting | Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284797) |
| November 17, 2025 | NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis | Xencor, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230353) |
| October 1, 2024 | NCT06619990 | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis | Xencor, Inc. | Phase 1/2 | Recruiting | Ulcerative Colitis (UC) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619990) |
| February 26, 2024 | NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06276491) |
| December 15, 2023 | NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Xencor, Inc. | Phase 1/2 | Terminated | Nonsquamous Non-small Cell Lung Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06173505) |
| August 22, 2023 | NCT06005792 | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis | Xencor, Inc. | Phase 1 | Terminated | Psoriasis, Atopic Dermatitis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06005792) |
| August 18, 2023 | NCT05996445 | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Terminated | Solid Tumors | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05996445) |
| October 18, 2022 | NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Completed | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05585034) |
| June 27, 2022 | NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Xencor, Inc. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433142) |
| April 14, 2022 | NCT05328102 | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory... | Xencor, Inc. | Phase 2 | Terminated | Diffuse Large-cell B-cell Lymphoma | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05328102) |
| September 2, 2021 | NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Xencor, Inc. | Phase 2 | Active not recruiting | Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate... | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05032040) |
| August 13, 2021 | NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant... | Xencor, Inc. | Phase 2 | Completed | Metastatic Castration-Resistant Prostate Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05005728) |
| April 23, 2021 | NCT04857866 | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers | Xencor, Inc. | Phase 1 | Completed | Safety in Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04857866) |
| October 19, 2020 | NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Xencor, Inc. | Phase 1/2 | Terminated | Merkel Cell Carcinoma, Small Cell Lung Cancer | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04590781) |
| February 21, 2019 | NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Completed | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849469) |
| November 26, 2018 | NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | Xencor, Inc. | Phase 1 | Completed | Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen... | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03752398) |
| May 7, 2018 | NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | Xencor, Inc. | Phase 1 | Completed | Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03517488) |
| February 26, 2018 | NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | Xencor, Inc. | Phase 1 | Terminated | Relapsed/ Refractory Multiple Myeloma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03445663) |
| January 26, 2018 | NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | Xencor, Inc. | Phase 1 | Completed | Neuroendocrine Tumor, Gastrointestinal Neoplasm | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03411915) |
| October 5, 2016 | NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | Xencor, Inc. | Phase 1 | Completed | B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02924402) |
| August 29, 2016 | NCT02881853 | Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195 | Xencor, Inc. | Phase 1 | Completed | Healthy Volunteers, Atopic Disease | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02881853) |
| August 15, 2016 | NCT02867098 | XmAb5871 Bioavailability Study | Xencor, Inc. | Phase 1 | Completed | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02867098) |
| April 6, 2016 | NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | Xencor, Inc. | Phase 1 | Completed | Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02730312) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Recruiting | 7 |
| Terminated | 6 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Endometrial Neoplasms | 5 |
| Carcinoma, Renal Cell | 5 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Ovarian Neoplasms | 4 |
| Uterine Cervical Neoplasms | 4 |
| Prostatic Neoplasms | 4 |
| Carcinoma, Transitional Cell | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Colorectal Neoplasms | 4 |
| Small Cell Lung Carcinoma | 4 |
| Triple Negative Breast Neoplasms | 4 |
| Fallopian Tube Neoplasms | 3 |
| Melanoma | 3 |
| Carcinoma, Hepatocellular | 3 |
| Nasopharyngeal Carcinoma | 3 |
| Liver Neoplasms | 3 |
| Stomach Neoplasms | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Inflammatory Bowel Diseases | 2 |
| Pancreatic Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Dermatitis, Atopic | 2 |
| Burkitt Lymphoma | 2 |
| Carcinoma, Ovarian Epithelial | 2 |
| Cholangiocarcinoma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
- [Burmese restaurants in the United States](https://specstream.ai/data/businesses/burmese-restaurants/united-states)
- [Pest control companies in the United States](https://specstream.ai/data/businesses/pest-control-companies/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
